
Lyndra Therapeutics eyes $180M Series D for potential 2026 launch of once-weekly schizophrenia med
With a Phase III trial now underway for a once-weekly, long-acting version of the antipsychotic med risperidone, Lyndra Therapeutics is eyeing a large Series D to push it through a 2025 NDA filing with the goal of taking it to market in 2026.
The biotech has closed the first tranche of the round, slightly over $20 million with the help of insiders, and is angling for $180 million total, Jessica Ballinger, president and operating chief, told Endpoints News on the sidelines of this year’s BIO confab in Boston. Lyndra is capitalizing on slow-release technology out of the MIT lab of Bob Langer, who is known in many circles but more broadly for work on the delivery tech for the mRNA Covid-19 vaccines.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.